EMA Reviews And Rare Disease Trends Will Open Global Markets
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
29 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$14.00
89.4% undervalued intrinsic discount15 Aug
US$1.48
1Y
52.4%7D
-3.9%